These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27271678)

  • 21. Diagnostics and susceptibility testing in Aspergillus.
    Bernal-Martínez L; Alastruey-Izquierdo A; Cuenca-Estrella M
    Future Microbiol; 2016; 11(2):315-28. PubMed ID: 26848512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-resistant aspergillosis due to cryptic species.
    Howard SJ
    Mycopathologia; 2014 Dec; 178(5-6):435-9. PubMed ID: 24969615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on antifungal resistance in Aspergillus and Candida.
    Arendrup MC
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():42-8. PubMed ID: 24372701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains.
    Alcazar-Fuoli L; Buitrago M; Gomez-Lopez A; Mellado E
    Virulence; 2015; 6(4):376-84. PubMed ID: 26065322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus.
    Lamoth F; Juvvadi PR; Steinbach WJ
    Crit Rev Microbiol; 2016; 42(2):310-21. PubMed ID: 25243616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms.
    Gao L; Sun Y
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7097-9. PubMed ID: 26303797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Keratomycosis caused by Aspergillus viridinutans: an Aspergillus fumigatus-resembling mold presenting distinct clinical and antifungal susceptibility patterns.
    Shigeyasu C; Yamada M; Nakamura N; Mizuno Y; Sato T; Yaguchi T
    Med Mycol; 2012 Jul; 50(5):525-8. PubMed ID: 22329455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azole resistance in Aspergillus: a growing public health menace.
    Denning DW; Perlin DS
    Future Microbiol; 2011 Nov; 6(11):1229-32. PubMed ID: 22082283
    [No Abstract]   [Full Text] [Related]  

  • 29. Animal models of invasive aspergillosis for drug discovery.
    Paulussen C; Boulet GA; Cos P; Delputte P; Maes LJ
    Drug Discov Today; 2014 Sep; 19(9):1380-6. PubMed ID: 24931219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence.
    Lionakis MS; Lewis RE; May GS; Wiederhold NP; Albert ND; Halder G; Kontoyiannis DP
    J Infect Dis; 2005 Apr; 191(7):1188-95. PubMed ID: 15747256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drosophila melanogaster as a model organism for invasive aspergillosis.
    Lionakis MS; Kontoyiannis DP
    Methods Mol Biol; 2012; 845():455-68. PubMed ID: 22328395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic re-identification and antifungal susceptibility testing of Aspergillus section Nigri strains of the BCCM/IHEM collection.
    Hendrickx M; Beguin H; Detandt M
    Mycoses; 2012 Mar; 55(2):148-55. PubMed ID: 21929560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antifungal drug resistance in Aspergillus.
    Moore CB; Sayers N; Mosquera J; Slaven J; Denning DW
    J Infect; 2000 Nov; 41(3):203-20. PubMed ID: 11120607
    [No Abstract]   [Full Text] [Related]  

  • 34. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.
    Verweij PE; Ananda-Rajah M; Andes D; Arendrup MC; Brüggemann RJ; Chowdhary A; Cornely OA; Denning DW; Groll AH; Izumikawa K; Kullberg BJ; Lagrou K; Maertens J; Meis JF; Newton P; Page I; Seyedmousavi S; Sheppard DC; Viscoli C; Warris A; Donnelly JP
    Drug Resist Updat; 2015; 21-22():30-40. PubMed ID: 26282594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus.
    Alastruey-Izquierdo A; Cuesta I; Houbraken J; Cuenca-Estrella M; Monzón A; Rodriguez-Tudela JL
    Med Mycol; 2010 Feb; 48(1):97-102. PubMed ID: 19296366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fungal Biofilms: Update on Resistance.
    Borghi E; Borgo F; Morace G
    Adv Exp Med Biol; 2016; 931():37-47. PubMed ID: 27115411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nonlethal murine cutaneous model of invasive aspergillosis.
    Ben-Ami R; Kontoyiannis DP
    Methods Mol Biol; 2012; 845():569-82. PubMed ID: 22328405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic of Fungal Infections Related to Biofilms.
    Sanguinetti M; Posteraro B
    Adv Exp Med Biol; 2016; 931():63-82. PubMed ID: 27300347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newer combination antifungal therapies for invasive aspergillosis.
    Steinbach WJ; Juvvadi PR; Fortwendel JR; Rogg LE
    Med Mycol; 2011 Apr; 49 Suppl 1(0 1):S77-81. PubMed ID: 20608784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.